Industry Briefs: July 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Industry Briefs: July 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Aug 2, 2012

Company News

Coldstream Laboratories is expanding its Louisville, Kentucky, sterile-manufacturing facility. Read More

Dendreon has announced a restructuring plan to reduce costs by approximately $150 million annually. The plan includes the closure of its Morris Plains, New Jersey, manufacturing facility. Read More

GlaxoSmithKline has announced the acquisition of 79% of Human Genome Sciences’s shares, and is beginning a subsequent offering period to acquire the remaining shares. Read More

NSF International has acquired Becker & Associates Consulting, a clinical, regulatory, and scientific-consulting firm. Read More

People Notes

Array BioPharma has named Andrew Robbins as senior vice-president of commercial operations. Read More

Daicel has appointed Dieter Heckmann as executive officer. He will assume responsibility for global operations of the Chiral Pharmaceutical Ingredients company, reporting to Misao Fudaba, president and CEO of Daicel.

Quanticate has appointed Sally Du Toit as vice-president of pharmacovigilance and Chris Cramer as vice-president of clinical data management. Read More

Takeda Pharmaceutical has appointed Christopher Hohman as vice-president of its corporate communications department. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Featured Jobs

More Jobs
8/2/2012
 Click here